SavedAdd your journal

Journals / Ankara Üniversitesi Eczacılık Fakültesi Dergisi / 2021 / Cilt: 45 - Sayı: 1

NANOTHERANOSTICS

NANOTERANOSTİKLER

Meliha EKİNCİ
Derya İLEM-ÖZDEMİR
Pages
131–155
Publication Date
2021-01-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, it is aimed to review the recent studies on these subjects by giving information about the theranostic concept, cancer nanotherapy, drug and gene delivery systems, nanoprobes, nanosensors, personalized therapy, and active and passive targeting.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In recent years, significant advances have been made in early diagnosis and treatment of diseases, thanks to advances in nanotechnology.
📊
Key Findings & Data:With the birth of the concept of “theranostic”, a concept that combines diagnostic imaging methods with therapeutic methods, cancer nanotherapy has started to rise rapidly.
💡
Conclusion & Impact:In this review, it is aimed to review the recent studies on these subjects by giving information about the theranostic concept, cancer nanotherapy, drug and gene delivery systems, nanoprobes, nanosensors, personalized therapy, and active and passive targeting.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Drug delivery systems · personalized medicine · nanotechnology

Abstract

Objective: In recent years, significant advances have been made in early diagnosis and treatment of diseases, thanks to advances in nanotechnology. With the birth of the concept of “theranostic”, a concept that combines diagnostic imaging methods with therapeutic methods, cancer nanotherapy has started to rise rapidly. In this review, it is aimed to review the recent studies on these subjects by giving information about the theranostic concept, cancer nanotherapy, drug and gene delivery systems, nanoprobes, nanosensors, personalized therapy, and active and passive targeting.

Özet

Amaç: Son yıllarda, nanoteknolojideki gelişmeler sayesinde hastalıkların erken teşhis ve tedavisinde önemli ilerlemeler kaydedilmektedir. Tanısal görüntüleme yöntemleriyle tedavi yöntemlerini birleştiren bir kavram olan “teranostik” kavramının doğmasıyla kanser nanotıbbı hızlı bir yükselişe geçmiştir. Bu derlemede, teranostik kavramı, kanser nanotıbbı, ilaç ve gen taşıyıcı sistem çeşitleri, nanogörüntüleme yöntemleri, nanoproblar, nanosensörler, kişiselleştirilmiş tedavi ve aktif ve pasif hedeflendirme ile ilgili bilgiler verilerek, son yıllarda bu konularda yapılmış olan çalışmaların gözden geçirilmesi amaçlanmıştır.

🔖

Cite This Article

EKİNCİ, M., İLEM-ÖZDEMİR, D. (2021). NANOTHERANOSTICS. Ankara Üniversitesi Eczacılık Fakültesi Dergisi, Cilt: 45 - Sayı: 1, 131–155. https://ajindex.com/articles/83250

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Sumer, B. and Gao, J. (2008). Theranostic nanomedicine for cancer. Nanomedicine, 3(2), 137– 140
  2. Kurdziel, K., Ravizzini, G., Croft, B.Y., Tatum, J.L., Choyke, P.L., Kobayashi, H. (2008). The evolving role of nuclear molecular imaging in cancer. Expert Opinion on Medical Diagnostics, 2(7), 829–842
  3. Bozkurt, M.F. and Özcan, Z. (2018). The evolving role of nuclear medicine and molecular imaging: theranostics and personalized therapeutic applications. Molecular Imaging and Radionuclide Therapy, 27, 1–2
  4. Aulić, S., Bolognesi, M.L., Legname, G. (2013). Small-molecule theranostic probes: A promising future in neurodegenerative diseases. International Journal of Cell Biology, 2013, 150952
  5. Kim, T.H., Lee, S. and Chen, X. (2013). Nanotheranostics for personalized medicine. Expert Review of Molecular Diagnostics, 13(3), 257–269
  6. Swierczewska, M., Liu, G., Lee, S., Chen, X. (2012). High-sensitivity nanosensors for biomarker detection. Chemical Society Reviews, 41(7), 2641–2655
  7. Chikkaveeraiah, B.V., Bhirde, A.A., Morgan, N.Y., Eden, H.S., Chen, X. (2012). Electrochemical immunosensors for detection of cancer protein biomarkers. ACS Nano, 6(8), 6546–6561
  8. Farokhzad, O.C. and Langer, R. (2006). Nanomedicine: Developing smarter therapeutic and diagnostic modalities. Advanced Drug Delivery Reviews, 58(14), 1456–1459
  9. Funkhouser, J. (2002). Reinventing pharma: The theranostic revolution. Current Drug Discovery, 2, 17–19
  10. Durak, H. (2015). Onkolojide kişiselleştirilmiş tedavi ve teranostik yaklaşımlar. Nükleer Tıp Seminerleri, (2), 80–4
  11. Kalash, R.S., Lakshmanan, V.K., Cho, C.-S., Park, I.-K. (2016). Theranostics. In: M. Ebara (Ed.), Biomaterials Nanoarchitectonics, (p. 197–215). 1st Edition. Elsevier Inc.: William Andrew
  12. Cancer Web site. (2018). Retrieved Jan 17, 2020, from https://www.who.int/news-room/fact sheets/detail/cancer
  13. Nayak, K.A. and Pal, D. (2010). Nanotechnology for targeted delivery in cancer therapeutics. Seemanta Institute of Pharmaceutical Sciences, 1(1), 1–7
  14. Wang, L.V. (2004). Ultrasound-mediated biophotonic imaging: A review of acousto-optical tomography and photo-acoustic tomography. Disease Markers, 19, 123–138
  15. Singh, K. (2005). Nanotechnology in cancer detection and treatment. Technology in Cancer Research and Treatment, 4, 583–584
  16. National Cancer Institute Web site. (2004). "Cancer Nanotechnology". Retrieved Jan 25, 2020, from
  17. Oylar, Ö. and Tekin, İ. (2011). N